Actively Recruiting
Restarting Triple Therapy With Robust Monitoring for Adverse Events (RETRIAL)
Led by Boston Children's Hospital · Updated on 2025-11-03
200
Participants Needed
18
Research Sites
161 weeks
Total Duration
On this page
Sponsors
B
Boston Children's Hospital
Lead Sponsor
C
Cystic Fibrosis Foundation
Collaborating Sponsor
AI-Summary
What this Trial Is About
RETRIAL is a multi-site observational study of people with Cystic Fibrosis (PWCF) ages 6 and up starting the new triple-therapy modulator (vanzacaftor/tezacaftor/deutivacaftor (VTD)), after having experienced neuropsychiatric events and/or liver injury while taking elexacaftor/tezacaftor/ivacaftor (ETI) that resulted in a modification or discontinuation of standard ETI dosing.
CONDITIONS
Official Title
Restarting Triple Therapy With Robust Monitoring for Adverse Events (RETRIAL)
Who Can Participate
Eligibility Criteria
You may qualify if you...
RETRIAL-Mental Health:
-
PWCF age 6 years and up (if age is < 12 years old, the PWCF's caregiver will complete daily diaries and surveys; see "Caregiver Participant Inclusion Criteria" below)
-
Eligible for VTD and intending to take it
-
Experienced new or worsening mental health symptoms after initiating ETI, which led to one of the following changes in treatment to currently taking:
- No modulators
- A modulator other than ETI
- A flipped dose of ETI
- A reduced dose of ETI
-
Willing to delay first VTD dose for short period of time to complete the Baseline assessments
-
Has access to a smart device (phone, tablet, etc.) capable of receiving messages with survey links
-
Is English-speaking.
RETRIAL-LIVER:
-
A person with CF age 6 years and up
-
Eligible for VTD and intending to take it
-
Experienced drug-induced liver injury (as defined by local care team) after initiating ETI, which led to one of the following changes in treatment to currently taking:
- no modulators; or
- a modulator other than ETI; or
- a reduced or altered dose of ETI;
-
Willing to delay first VTD dose for short period of time to complete the Baseline assessments
-
Has access to a smart device (phone, tablet, etc.) capable of receiving messages with survey links
-
Is English-speaking.
You will not qualify if you...
RETRIAL-Mental Health:
- Cannot access VTD
- Currently, or prior history of, taking VTD
- Unable or unwilling to follow protocol
- If <12 years old, having another <12-year-old person in the same household consented into the study
- Is actively listed on any transplant list, or within 3 months post-transplant surgery
- Is currently pregnant (test not required)
- Anticipated change in CF Care Centers in the next 6 months
- Any situation that, in the opinion of the Investigator, would compromise the safety of the patient or the quality of the data.
RETRIAL-LIVER:
- Cannot access VTD
- Currently, or prior history of, taking VTD
- Unable or unwilling to follow protocol
- If <12 years old, having another <12-year-old person in the same household consented into the study
- Any severe, decompensated liver disease (e.g. Child-Pugh, Class C)
- Is actively listed on any transplant list, or within 3 months post-transplant surgery (any organ), or history of liver transplant
- Is currently pregnant (test not required)
- Anticipated change in CF Care Centers in the next 6 months
- Any situation that, in the opinion of the Investigator, would compromise the safety of the patient or the quality of the data.
Caregiver Participant:
Inclusion Criteria:
- Is a primary, daily caregiver of a person with CF under the age of 12 enrolled in the study
- Has access to smart device (phone, tablet, etc.) capable of receiving messages with survey links
- Is able to read and complete surveys and Daily Diary in English.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 18 locations
1
University of Alabama at Birmingham
Birmingham, Alabama, United States, 35233
Actively Recruiting
2
Children's Hospital Colorado
Aurora, Colorado, United States, 80045
Actively Recruiting
3
National Jewish Health
Denver, Colorado, United States, 80206
Actively Recruiting
4
Nemours Children's
Wilmington, Delaware, United States, 19803
Actively Recruiting
5
Nemours Children's
Jacksonville, Florida, United States, 32207
Actively Recruiting
6
Nemours Children's
Orlando, Florida, United States, 32827
Actively Recruiting
7
Nemours Children's
Pensacola, Florida, United States, 32514
Actively Recruiting
8
Emory University
Atlanta, Georgia, United States, 30322
Actively Recruiting
9
Indiana University
Bloomington, Indiana, United States, 47405
Actively Recruiting
10
Kansas University Medical Center
Kansas City, Kansas, United States, 66160
Actively Recruiting
11
Johns Hopkins University
Baltimore, Maryland, United States, 21287
Actively Recruiting
12
Massachusetts General Hospital
Boston, Massachusetts, United States, 02114
Not Yet Recruiting
13
Boston Children's Hospital
Boston, Massachusetts, United States, 02215
Actively Recruiting
14
University of Michigan
Ann Arbor, Michigan, United States, 48109
Actively Recruiting
15
Washington University at St. Louis
St Louis, Missouri, United States, 63130
Not Yet Recruiting
16
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania, United States, 15224
Actively Recruiting
17
University of Texas Southwestern Medical Center
Dallas, Texas, United States, 75235
Actively Recruiting
18
Seattle Children's Hospital
Seattle, Washington, United States, 98105
Actively Recruiting
Research Team
E
Evelyn Bord, BS
CONTACT
C
Callie Bacon, MPH
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here